secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001193125-26-199061
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Q1 2026: GAAP EPS -$0.80, revenue $71.1M, reiterates FY2026 guidance
----------------------------------------------------------------------------

- GAAP net loss of $24.8M ($0.80/share); non-GAAP loss of $11.0M ($0.36/share).
- Revenue $71.1M; GAAP gross margin 30.2%, non-GAAP gross margin 32.3%.
- Adjusted EBITDA loss of $15.2M in Q1 2026.
- Cash, equivalents, restricted cash & marketable securities $604.7M; expects ~$106M tax refund.
- Bought back ~2.6M shares for $40.1M in Q1; FY2026 revenue guidance reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000119312526199061/0001193125-26-199061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000119312526199061/flgt-20260501.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-199061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer